Phase 3 clinical trial E1912
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912. The results show that the combination of ibrutinib, a Bruton’s tyrosine kinase inhibitor, and the antibody therapy rituximab, continue to provide superior progression-free survival and overall survival compared to standard chemoimmunotherapy for patients (aged 70 or younger) with previously untreated chronic lymphocytic leukemia (CLL). The analysis provides new safety and efficacy information on the patients in E1912 who completed ibrutinib plus rituximab therapy and continued to receive ibrutinib for as long as it remained effective.
Voor andere berichten over phase III berichten, KLIK HIER!
